Edition:
India

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

20.68USD
22 Jun 2018
Change (% chg)

$1.55 (+8.10%)
Prev Close
$19.13
Open
$19.29
Day's High
$20.68
Day's Low
$19.05
Volume
9,640
Avg. Vol
3,691
52-wk High
$21.71
52-wk Low
$5.70

Latest Key Developments (Source: Significant Developments)

Acer Therapeutics Announces Closing Of Underwritten Public Offering Of Common Stock
Friday, 15 Dec 2017 

Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.  Full Article

Acer Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - ANNOUNCED PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 916,667 SHARES OF COMMON STOCK AT $12.00/SHARE.  Full Article

Acer Therapeutics Announces Proposed Underwritten Public Offering Of Common Stock
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Acer Therapeutics Inc ::ACER THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ACER THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO FUND RESEARCH AND DEVELOPMENT EFFORTS, TO SEEK REGULATORY APPROVAL FOR EDSIVO.ACER THERAPEUTICS INC - ALSO INTENDS TO USE NET PROCEEDS FROM OFFERING TO INVEST IN PRE-COMMERCIAL ACTIVITIES FOR EDSIVO, AMONG OTHERS.  Full Article

Acer Therapeutics Q3 loss per share $1.09
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Acer Therapeutics Inc ::Acer Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $1.09.  Full Article

Opexa Therapeutics reports Q2 loss per share $0.30
Friday, 12 Aug 2016 

Opexa Therapeutics Inc : Opexa Therapeutics reports second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.30 .Q2 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Acer Therapeutics Q4 Loss Per Share $0.63

* ACER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE